Compounding: Sterile & Non-Sterile Preparations for the DHA / DoH / MOH Prometric Assessment Exam

Introduction: The Crucial Role of Compounding in Pharmacy Practice and Your Prometric Exam

As aspiring pharmacists preparing for the DHA / DoH / MOH Prometric Assessment, understanding pharmaceutical compounding is not merely academic; it is foundational to safe and effective patient care. Compounding allows pharmacists to customize medications to meet unique patient needs that cannot be fulfilled by commercially manufactured products. This includes tailoring dosages, creating allergen-free formulations, preparing drugs in alternative dosage forms, or combining multiple medications into a single preparation.

The Prometric Assessment, as of April 2026, places significant emphasis on compounding principles, particularly distinguishing between sterile and non-sterile preparations. This topic frequently appears in various question formats, testing your knowledge of U.S. Pharmacopeia (USP) standards, safety protocols, calculations, and best practices. A solid grasp of these concepts is indispensable for both passing your exam and excelling in your future practice in the UAE and other Gulf regions.

Key Concepts: Differentiating Sterile and Non-Sterile Compounding

Pharmaceutical compounding is distinct from manufacturing. While manufacturing involves large-scale production of standardized drug products, compounding focuses on preparing specific medications for individual patients based on a prescription. This personalized approach is vital, but it also carries significant responsibilities regarding quality, safety, and regulatory compliance.

Non-Sterile Compounding (USP General Chapter <795>)

Non-sterile compounding, also known as "traditional compounding," involves preparing medications that do not need to be sterile. These preparations are typically for routes of administration where sterility is not a primary concern, such as oral, topical, rectal, or vaginal applications. USP General Chapter <795> provides the standards for quality, strength, purity, and appropriate packaging and labeling of compounded non-sterile preparations (CNSPs).

• Definition: The preparation of a drug or device in anticipation of or in response to a prescription drug order for a specific patient.
• Common Dosage Forms:
  • Oral liquids (solutions, suspensions, emulsions)
  • Capsules and powders
  • Topical preparations (creams, ointments, gels, lotions)
  • Suppositories and troches
  • Transdermal preparations (non-sterile patches)
• Facilities and Equipment: Non-sterile compounding typically requires a designated compounding area that is clean, well-lit, and away from high-traffic areas. Essential equipment includes balances, glassware, spatulas, mortars and pestles, and appropriate measuring devices. The area should be easy to clean and maintain.
• Beyond-Use Date (BUD): For non-sterile preparations, the BUD is determined based on the water content of the formulation and stability data, if available. USP <795> provides general guidelines for BUDs when specific stability data is lacking:
  • Non-aqueous formulations: Not more than the intended duration of therapy or 6 months, whichever is earlier.
  • Water-containing oral formulations: Not more than 14 days when stored at controlled cold temperatures.
  • Water-containing topical/dermal and mucosal liquid and semisolid formulations: Not more than 30 days.

Sterile Compounding (USP General Chapter <797>)

Sterile compounding involves preparing medications that must be free from microorganisms, pyrogens, and particulate matter. These preparations are critical for patient safety, as they are typically administered directly into the bloodstream, eyes, or spinal fluid. USP General Chapter <797> sets the standards for compounding sterile preparations (CSPs) to prevent contamination.

• Definition: The preparation of a drug or device in a manner intended to prevent contamination by microorganisms and endotoxins.
• Common Dosage Forms:
  • Intravenous (IV) solutions (e.g., total parenteral nutrition, chemotherapy)
  • Ophthalmic preparations
  • Injections (intramuscular, subcutaneous, intrathecal)
  • Irrigations for internal body cavities
• Environmental Controls: Sterile compounding requires a highly controlled environment to minimize contamination. This typically includes:
  • Cleanroom: A classified area with specific air quality standards (ISO classifications).
  • Primary Engineering Control (PEC): Devices that provide an ISO Class 5 environment, such as:
    • Laminar Airflow Workbenches (LAFWs)
    • Compounding Aseptic Isolators (CAIs)
    • Biological Safety Cabinets (BSCs) - especially for hazardous sterile compounding.
  • Secondary Engineering Control (SEC): The room surrounding the PEC, typically an ISO Class 7 buffer room and an ISO Class 8 ante-room.
• Personnel Training and Garbing: Personnel involved in sterile compounding must undergo rigorous training, including media fill tests, and adhere to strict garbing procedures (e.g., sterile gloves, gowns, masks, hair covers) to prevent contamination.
• Risk Levels for CSPs: USP <797> categorizes CSPs into three risk levels based on the potential for microbial contamination:
  1. Low-Risk: Compounded under ISO Class 5 conditions using only sterile ingredients and devices, with minimal manipulations (e.g., transferring a sterile drug from a vial to a sterile IV bag). BUDs are longer than immediate-use.
  2. Medium-Risk: Involves multiple individual or small doses of sterile products combined to prepare a CSP that will be administered to multiple patients or to one patient on multiple occasions (e.g., TPN, pooling multiple vials). The compounding process is more complex or takes a longer duration.
  3. High-Risk: Prepared from non-sterile ingredients or with non-sterile devices, or in an environment less than ISO Class 5 for more than 1 hour. Any exposure to air quality worse than ISO Class 5 for more than 1 hour, or if non-sterile water-containing preparations are stored for more than 6 hours before sterilization. Sterilization of the final product is required.
• Beyond-Use Date (BUD) for CSPs: BUDs for sterile preparations are assigned based on the risk level, storage conditions (room temperature, refrigerated, frozen), and sterility testing results. USP <797> provides detailed tables for BUDs based on these factors.

Handling Hazardous Drugs (USP General Chapter <800>)

USP General Chapter <800> provides standards for handling hazardous drugs (HDs) to minimize the risk of exposure to healthcare personnel, patients, and the environment. This chapter applies to all healthcare personnel who handle HDs and all entities that store, prepare, transport, or administer HDs, regardless of whether they are sterile or non-sterile.

• Key Principles: Containment, personnel protection, and environmental safety.
• Engineering Controls:
  • Containment Primary Engineering Control (C-PEC): Ventilated device that provides worker protection from hazardous drugs (e.g., Class II or III Biological Safety Cabinet, Compounding Aseptic Containment Isolator).
  • Containment Secondary Engineering Control (C-SEC): Room where the C-PEC is located (e.g., negative pressure buffer room for sterile HDs, externally vented room for non-sterile HDs).
• Personal Protective Equipment (PPE): Specific PPE (e.g., double gloves, impermeable gowns, respiratory protection) is required when handling HDs during compounding, administration, and disposal.

How It Appears on the Exam: DHA / DoH / MOH Prometric Assessment Scenarios

The Prometric Assessment frequently tests your knowledge of compounding through various question styles. You can expect:

• Multiple-Choice Questions (MCQs): These will test your recall of USP chapter numbers, definitions (e.g., BUD, ISO classifications), risk levels, and specific guidelines.
• Case Studies: You might be presented with a patient scenario requiring a compounded preparation. You'll need to identify the appropriate type of compounding (sterile/non-sterile), determine the correct BUD, recommend suitable facilities/equipment, or identify potential errors.
• Calculations: Expect questions involving concentration calculations, dilutions, and, most importantly, determining the correct Beyond-Use Date (BUD) based on given compounding conditions and USP guidelines.
• Identification of Non-Compliance: Questions may describe a compounding process and ask you to identify violations of USP <795>, <797>, or <800> standards. For example, identifying an incorrect garbing procedure or an inappropriate BUD assignment.
• Hazardous Drug Handling: Scenarios involving the safe handling, storage, and disposal of hazardous drugs, including appropriate engineering controls and PPE.

For additional practice and to familiarize yourself with the question styles, explore the DHA / DoH / MOH Prometric Assessment practice questions available on PharmacyCert.com.

Study Tips: Efficient Approaches for Mastering Compounding

Mastering compounding for your Prometric exam requires a structured approach. Here are some effective study tips:

1. Deep Dive into USP Chapters: Focus on the core content of USP <795>, <797>, and <800>. Understand the rationale behind each standard. Pay close attention to the tables for BUDs in both <795> and <797>.
2. Create Comparison Charts: Develop tables or diagrams to clearly differentiate between sterile and non-sterile compounding. Compare:
   • Purpose and routes of administration
   • Facility requirements (e.g., cleanroom vs. designated area)
   • Equipment (e.g., LAFW vs. mortar and pestle)
   • Personnel garbing and training
   • BUD determination factors
   • Risk levels (for sterile)
3. Practice BUD Calculations: This is a critical and frequently tested area. Work through numerous examples of determining BUDs for various non-sterile formulations and sterile risk levels under different storage conditions. Understand the "lesser of" rule when applying BUD guidelines.
4. Understand ISO Classifications: Memorize the particle count limits for ISO Class 5, 7, and 8 environments. Understand where each class is required in a sterile compounding facility.
5. Focus on Hazardous Drug Safety: Know the specific requirements of USP <800>, including types of engineering controls (C-PEC, C-SEC), negative pressure requirements, and appropriate PPE for different activities (receipt, storage, compounding, administration).
6. Review Definitions and Terminology: Be clear on terms like aseptic technique, media fill test, primary engineering control (PEC), secondary engineering control (SEC), and segregated compounding area (SCA).
7. Utilize Practice Questions: Regularly test your knowledge with free practice questions and full-length exams. This helps identify areas where you need further study and familiarizes you with the exam format.
8. Visualize the Process: If possible, watch videos or review diagrams of sterile and non-sterile compounding processes. Visualizing the steps can help solidify your understanding of the environmental and procedural requirements.

Common Mistakes: What to Watch Out For

Candidates often stumble on specific aspects of compounding. Being aware of these common pitfalls can help you avoid them:

• Misinterpreting Beyond-Use Dates (BUDs): Incorrectly applying BUD guidelines is a frequent error. Remember that BUDs are not expiration dates and are determined differently for sterile vs. non-sterile preparations, and also by risk level and storage. Always choose the shortest applicable BUD.
• Confusing Sterile Risk Levels: Mixing up the definitions or requirements for low, medium, and high-risk sterile compounding can lead to incorrect answers regarding BUDs, environmental controls, or process complexity.
• Neglecting Environmental Controls: Underestimating the importance of ISO classifications, air pressure differentials, and PEC/SEC requirements for sterile compounding.
• Overlooking Hazardous Drug Precautions: Failing to recognize when a drug is hazardous and therefore requires adherence to USP <800> standards, including specific engineering controls and PPE.
• Lack of Attention to Detail: Compounding questions often hinge on precise details—e.g., "sterile non-hazardous drug" versus "sterile hazardous drug." Read questions carefully.
• Assuming All Compounding is the Same: Forgetting the fundamental differences in purpose, environment, and risk mitigation strategies between sterile and non-sterile preparations.

Quick Review / Summary

Compounding, both sterile and non-sterile, is a cornerstone of individualized patient care and a critical topic for your DHA / DoH / MOH Prometric Assessment. Non-sterile compounding (USP <795>) addresses preparations like oral liquids, creams, and capsules, focusing on quality and stability. Sterile compounding (USP <797>) deals with parenteral, ophthalmic, and other preparations requiring absolute sterility, emphasizing aseptic technique, environmental controls (ISO classifications), and risk levels (low, medium, high).

Furthermore, USP <800> provides essential guidelines for handling hazardous drugs, ensuring the safety of personnel and the environment, irrespective of whether the compounding is sterile or non-sterile. For your exam, focus on understanding these USP chapters, differentiating between the compounding types, mastering BUD calculations, and recognizing appropriate safety and quality control measures. Your ability to apply these principles will be tested through various scenarios and questions, making a thorough understanding indispensable for your success.